Hirano Masaki, Sahashi Kentaro, Ichikawa Yuki, Katsuno Masahisa, Natsume Atsushi
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan.
Craif Inc., Tokyo, Japan.
PLoS One. 2024 Aug 1;19(8):e0308179. doi: 10.1371/journal.pone.0308179. eCollection 2024.
Spinal muscular atrophy (SMA) is an intractable neuromuscular disorder primarily caused by homozygous deletions in exon 7 of the SMN1 gene. Early diagnosis and prompt treatment of patients with SMA have a significant impact on prognosis, and several therapies have recently been developed. Current SMA screening tests require a significant turnaround time to identify patients with suspected SMA, due both to the interval between the birth of a newborn and the collection of blood for newborn mass screening and the difficulty in distinguishing between SMN1 and SMN2, a paralog gene that requires testing in specialized laboratories. The aim of this study was therefore to develop a novel SMA screening assay that can be rapidly performed in ordinary hospitals and clinics to overcome these issues. We designed over 100 combinations of forward and reverse primers with 3' ends targeting SMN1-specific sites around exon 7, and evaluated their specificity and amplification efficiency by quantitative PCR to identify the best primer pair. Furthermore, we performed a single-stranded tag hybridization assay after PCR. To evaluate the accuracy and practicality of the newly developed assay, we analyzed saliva specimens from five patients with SMA and two SMA carriers collected in an outpatient clinic and DNA specimens from three patients with SMA and four SMA carriers from a biobank, together with those from healthy individuals. DNA and raw saliva specimens from all patients with SMA demonstrated a biallelic loss of SMN1, whereas those from carriers and healthy individuals did not. The results of 50 independent experiments were consistent for all samples. The assay could be completed within one hour. This simple and convenient new screening tool has the potential to allow patients with SMA to receive disease-modifying therapies within a shorter timeframe.
脊髓性肌萎缩症(SMA)是一种难治性神经肌肉疾病,主要由SMN1基因第7外显子的纯合缺失引起。SMA患者的早期诊断和及时治疗对预后有重大影响,最近已开发出几种治疗方法。目前的SMA筛查测试需要很长的周转时间来识别疑似SMA患者,这既是因为新生儿出生与采集用于新生儿群体筛查的血液之间存在时间间隔,也是因为难以区分SMN1和SMN2,后者是一个旁系同源基因,需要在专业实验室进行检测。因此,本研究的目的是开发一种新型SMA筛查检测方法,该方法可以在普通医院和诊所快速进行,以克服这些问题。我们设计了100多种正向和反向引物组合,其3'端靶向第7外显子周围的SMN1特异性位点,并通过定量PCR评估它们的特异性和扩增效率,以确定最佳引物对。此外,我们在PCR后进行了单链标签杂交检测。为了评估新开发检测方法的准确性和实用性,我们分析了在门诊收集的5例SMA患者和2例SMA携带者的唾液标本、来自生物样本库的3例SMA患者和4例SMA携带者的DNA标本,以及健康个体的标本。所有SMA患者的DNA和原始唾液标本均显示SMN1双等位基因缺失,而携带者和健康个体的标本则未显示。所有样本的50次独立实验结果均一致。该检测可在一小时内完成。这种简单方便的新筛查工具有可能使SMA患者在更短的时间内接受疾病修饰疗法。